164 results on '"Etheridge, Amy S."'
Search Results
2. Sequencing of genes of drug response in tumor DNA and implications for precision medicine in cancer patients
3. KDR genetic predictor of toxicities induced by sorafenib and regorafenib
4. Identification of Reduced ERAP2 Expression and a Novel HLA Allele as Components of a Risk Score for Susceptibility to Liver Injury Due to Amoxicillin-Clavulanate
5. Author response: Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD)
6. Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD)
7. Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients
8. PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors
9. Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients
10. Plasma levels of angiopoietin-2, VEGF-A, and VCAM-1 as markers of bevacizumab-induced hypertension: CALGB 80303 and 90401 (Alliance)
11. A resource for integrated genomic analysis of the human liver
12. Genomic Characterization of Metformin Hepatic Response.
13. Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD).
14. Germlinecisvariant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD)
15. Correction to: PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors
16. Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients
17. Optimal Sampling Strategies for Irinotecan (CPT-11) and its Active Metabolite (SN-38) in Cancer Patients
18. Supplementary Methods and Materials from Genetic Variants of VEGFA and FLT4 Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib
19. Table S1 from Genetic Variants of VEGFA and FLT4 Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib
20. Data from Genetic Variants of VEGFA and FLT4 Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib
21. Figure S1 from Genetic Variants of VEGFA and FLT4 Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib
22. Supplementary Data from Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance)
23. An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance)
24. Genetic variation determines VEGF-A plasma levels in cancer patients
25. Identification and single-base gene-editing functional validation of a cis-EPO variant as a genetic predictor for EPO-increasing therapies
26. Polygenic Risk Scores for Blood Pressure to Assess the Risk of Severe Bevacizumab‐Induced Hypertension in Cancer Patients (Alliance)
27. Correction to: PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors
28. Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients
29. PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors
30. Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients
31. Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients
32. Genome‐wide association studies of survival in 1520 cancer patients treated with bevacizumab‐containing regimens
33. Genetic effects on liver chromatin accessibility identify disease regulatory variants
34. Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage I–III Non–Small-Cell Lung Cancer
35. Liver Expression Quantitative Trait Loci (eQTL) and Related Approaches in Pharmacogenomic Studies
36. Plasma levels of angiopoietin-2, VEGF-A, and VCAM-1 as markers of bevacizumab-induced hypertension: CALGB 80303 and 90401 (Alliance)
37. Discovery and Functional Assessment of Gene Variants in the Vascular Endothelial Growth Factor Pathway
38. KDRgenetic predictor of toxicities induced by sorafenib and regorafenib
39. Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance)
40. A Common Allele in FGF21 Associated with Sugar Intake Is Associated with Body Shape, Lower Total Body-Fat Percentage, and Higher Blood Pressure
41. Genome‐wide association studies of survival in 1520 cancer patients treated with bevacizumab‐containing regimens.
42. A New Liver Expression Quantitative Trait Locus Map From 1,183 Individuals Provides Evidence for Novel Expression Quantitative Trait Loci of Drug Response, Metabolic, and Sex‐Biased Phenotypes
43. Genetic Variants of VEGFA and FLT4 Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib
44. The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation
45. Abstract 1625: Clinical biomarkers of survival in renal cell carcinoma patients treated with sorafenib
46. PIK3R5genetic predictors of hypertension induced by VEGF-pathway inhibitors
47. Functional
48. Chapter 7 - Liver Expression Quantitative Trait Loci (eQTL) and Related Approaches in Pharmacogenomic Studies
49. Discovery and Functional Assessment of Gene Variants in the Vascular Endothelial Growth Factor Pathway
50. Metabolism and disposition of [14C]n-butyl-p-hydroxybenzoate in male and female Harlan Sprague Dawley rats following oral administration and dermal application
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.